Vivanza Biosciences delivered impressive financial performance in the quarter ended June 2026, with consolidated net profit surging 66.67% to ₹0.15 crore compared to ₹0.09 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's operational efficiency improvements during the quarter.
The company's sales revenue increased 3.91% to ₹9.29 crore in Q1 FY2026, up from ₹8.94 crore in the same quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates steady business expansion despite challenging market conditions, with the company maintaining its market position in the biosciences sector.
The company's operating profit margin (OPM) improved to -0.86% in Q1 FY2026 from 1.68% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin improvement reflects better cost management and operational efficiency despite the negative OPM, indicating the company's focus on profitability over pure revenue growth.
Profit before depreciation and tax (PBDT) rose 111% to ₹0.19 crore in the quarter ended June 2026, compared to ₹0.09 crore in the same quarter of the previous year. As reported by Business Standard, this substantial increase in pre-tax profit demonstrates the company's enhanced operational performance and effective cost control measures during the quarter.
Vivanza Biosciences currently trades at ₹1.89 as of August 7, 2026, showing minimal movement from the previous day's close of ₹1.9. The stock has a market capitalization of ₹7.56 crore and maintains a PE ratio of 19.17 and PB ratio of 1.73. The company's 52-week high stands at ₹2.72 while the 52-week low is ₹1.52, indicating significant volatility in recent trading periods.
